‘Buy American’ Executive Order Could Impact Specialty Drugs

President Donald Trump has issued another executive order focused on the pharmaceutical industry: a so-called “Buy American” order. While the approach presents some benefits, industry experts maintain that several challenges exist to its implementation, not the least of which is that it’s coming in the middle of a pandemic. And multiple specialty therapies may be impacted by it.

The order, signed Aug. 6, comes only a couple of weeks after the president signed a handful of executive orders focused on drug pricing. One of them, a most-favored nation order, was criticized by industry experts as a last-ditch effort before the Nov. 3 election to show the country that the administration is doing something about drug prices (RSP 8/20, p. 1). At the same time, critics argued that it’s taking away from efforts to develop therapeutics and vaccines for the COVID-19 pandemic. The president held off on publicizing that order with the other three on July 24, saying that he was giving pharma one month to come up with alternatives. As of RSP press time on Sept. 9, that order had not been made public.

© 2024 MMIT
Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

woman-holding-bowel
June 13

Studies Reveal Impact of SonarMD Program on Managing IBD

READ MORE
pills-and-bills
June 13

Report: Led by Anti-Inflammatories, Specialty Drugs Continue Upward Trend

READ MORE
fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
June 13

New FDA Approvals: FDA Expanded Mircera’s Patient Population

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today